16 Amendments of Assita KANKO related to 2022/0009(COD)
Amendment 99 #
Proposal for a regulation
Recital 3
Recital 3
(3) Whereas its general objective is still valid and should be retained, Regulation (EC) No 1920/2006 as such no longer fits for addressing the current and future drug challenges. Therefore, the mandate of the European Monitoring Centre for Drugs and Drug Addiction should be revised, including its replacement, reinforcement and renaming into “European Union Drugs Agency” (‘the Agency’). Since substantial amendments to Regulation (EC) No 1920/2006 are needed to accommodate the common approach for Union decentralised agencies48 and to take account of the developments of the drug phenomenon, in the interest of clarity that Regulation should be replaced by a new Regulation. _________________ 48 Joint Statement of the European Parliament, the Council of the EU and the European Commission on decentralised agencies of 19 July 2012, https://european- union.europa.eu/sites/default/files/docs/bod y/joint_statement_and_common_approach _2012_en.pdf.
Amendment 101 #
Proposal for a regulation
Recital 4
Recital 4
(4) The main focus of Regulation (EC) No 1920/2006 was on health-related issues. However, addressing also drug production, drug markets and drug supply issues, is necessary to understand the impacts of the drug phenomenon on public health, reduce the availability of drugs in the Union and curb drug demand. Health- and supply-related issues are intrinsically linked. TIn order to provide factual, objective, reliable, comparable and Union-wide significant data and analysis, the Agency should therefore address the drug phenomenon more holisticallyin a multidisciplinary way, taking into account drug use, drug addictions, prevention, treatment, care, risk and harm reduction, rehabilitation, social reintegration and recovery, drug supply, including illicit production and trafficking, and other relevant drug related issues such as violence, criminality and their consequences.
Amendment 103 #
Proposal for a regulation
Recital 4 a (new)
Recital 4 a (new)
(4 a) The Agency, in cooperation with other Union bodies, offices and agencies, should also focus on and extend its activities to developing areas of cooperation with Member States regarding monitoring of drug trafficking, the illegal drugs markets and drug-related crime.
Amendment 115 #
Proposal for a regulation
Recital 9
Recital 9
(9) The collection, analysis and dissemination of data should continue to be the main task of the Agency. The standard data is collected through the national focal points, which should remain one of the main data providers for the Agency. Additional, closer to real-time data sources are increasingly available through innovative data collection methods. Therefore, the Agency should have access to all data available to get a holistic picture of the drug phenomenon in the Union and the external factors influencing it and should always keep the national focal points informed.
Amendment 116 #
Proposal for a regulation
Recital 9 a (new)
Recital 9 a (new)
(9 a) The national focal points are key national players with respect to improving data collection methodologies and tools, and developing relevant guidelines for their implementation. In addition, the national focal points participate in the early warning system and report on new trends in the use of existing psychoactive substances and on new consumption patterns involving combinations of psychoactive substances which pose a potential health risk. Moreover, they provide training to persons dealing with prevention and offer support in the production of different products of the Agency.
Amendment 117 #
Proposal for a regulation
Recital 10
Recital 10
(10) TNational focal points represent the cornerstone of the Union drug monitoring and reporting system. It is therefore essential that the relationship between the Agency and the national focal points is a symbiotic and mutually-reinforcing one and that the data requirements of the Agency should bare mirrored in the national focal points. They should be empowered within the Member States to receive all relevant data from the different national authorities. Data collection in the Member States should be streamlined as far as possible to avoid double reporting and duplication of efforts.
Amendment 122 #
Proposal for a regulation
Recital 14
Recital 14
(14) The drug phenomenon is becoming more and more technology-enabled, as was shown again during the COVID-19 pandemic where a greater adoption of new technologies to facilitate drug distribution has been observed. It is estimated that about two-thirds of the offers on darknet markets are drug-related. Drug trading is using different platforms, including social media networks and mobile applications. This development is mirrored in responses to the drug phenomenon, with an increased use of internet communications , mobile applications and e-health interventions. The Agency, together with other relevant Union agencies and avoiding duplication of efforts, should monitor such developments as part of its holistic approach to the drug phenomenon.
Amendment 155 #
Proposal for a regulation
Article 4 – paragraph 1
Article 4 – paragraph 1
The Agency shall provide the Union and its Member States with factual, objective, reliable and comparable information, early warning and risk assessment at Union level concerning drugs use, drug addiction, drug marketss, prevention, treatment, care, risk and harm reduction, rehabilitation, social reintegration and recovery, drug supply, including illicit production and trafficking, and other relevant drug related issues such as drug-related violence, drug criminality and drug trafficking and their consequences, and to recommend appropriate and concrete, evidence-based actions on how to address the related challenges in a timely manner.
Amendment 161 #
Proposal for a regulation
Article 5 – paragraph 1 – point b – point 2
Article 5 – paragraph 1 – point b – point 2
(2) health and security threat assessment and preparedness pursuant to Article 12;
Amendment 171 #
Proposal for a regulation
Article 5 – paragraph 7
Article 5 – paragraph 7
7. In carrying out and implementing the tasks referred to in paragraph 1, the Agency shall cooperate actively with other Union decentralisedbodies, offices, agencies and bodies, in particular Europol, Eurojust, Cepol, the European Medicines Agency, the European Centre for Disease Prevention and Control, civil society organisations and other relevant stakeholders, to attain maximum efficiency in monitoring, assessing and responding to the drugs phenomenon.
Amendment 211 #
Proposal for a regulation
Article 7 – paragraph 2 a (new)
Article 7 – paragraph 2 a (new)
2 a. The Agency shall, in cooperation with the national focal points, develop tools and instruments to help Member States to monitor and evaluate their national policies .
Amendment 226 #
Proposal for a regulation
Article 12 – title
Article 12 – title
Amendment 230 #
Proposal for a regulation
Article 12 – paragraph 1
Article 12 – paragraph 1
1. The Agency shall develop a strategic generalhealth and security threat assessment capability to identify at an early stage new developments of the drugs phenomenon that have a potential to impact negatively on public health, safety and security and, through doing so, to help increase the preparedness of the relevant stakeholders to respond to new threats in a timely and effective manner.
Amendment 235 #
Proposal for a regulation
Article 12 – paragraph 5
Article 12 – paragraph 5
5. The Agency shall cooperate closely with Member States and with other Union decentralised agencies and bodies, and Union and international organisations in carrying out a threat assessment by involving them in the assessment as appropriate. Where the potential threat is already subject to an analysis under another Union mechanism, the Agency shall not carry out a threat assessment.
Amendment 246 #
Proposal for a regulation
Article 13 – paragraph 2 – point f a (new)
Article 13 – paragraph 2 – point f a (new)
(f a) security risks
Amendment 321 #
Proposal for a regulation
Article 33 – paragraph 2 – point h a (new)
Article 33 – paragraph 2 – point h a (new)
(h a) (ia) nominate, where appropriate, national experts for the discussions on the relevant indicators and for other ad-hoc and targeted data collection exercises;